USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: BIOSENSE TECHNOLOGIES, INC.
Address: 4 ARROW DR
WOBURN, MA 01801-2040
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: (781) 933-3635

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,424,454.00 10
SBIR Phase II $2,199,977.00 3

Award List:

Rapid Antibiotic Susceptibility Testing

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ronald J. Rieder
Award Amount: $476,168.00
Abstract:
DESCRIPTION (provided by applicant): The development of a new method for the diagnostic testing of Mycobacterium tuberculosis having unparalleled speed and simplicity is proposed. The technical approach is based on a novel implementation of impedance sensing to monitor cellular growth with… More

Ultra-Sensitive Detection of Protein-Ligand Interactions

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ronald J. Rieder
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The development of an evanescent wave biosensor enabling the monitoring of binding interactions of small weakly interacting bio-molecules (MW

SBIR Phase I: Precision Refractometry for Chemical Detection

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: NSF
Principal Investigator: Ronald Rieder
Award Amount: $100,000.00
Abstract:
This Small Business Innovation Research Phase I project describes a compact and low-cost optical based system for the rapid detection of chemicals. The detector system relies on precision measurements of refractive index changes from analytes absorbed within a thin film polymer coating. … More

SBIR Phase I: Rapid Antibiotic Susceptibility Testing

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: NSF
Principal Investigator: Ronald Rieder
Award Amount: $100,000.00
Abstract:
This Small Business Innovation Research (SBIR)Phase I proposes to develop a new method for antibiotic susceptibility testing having unparalleled speed and simplicity. The technical approach is based on a novel implementation of impedance sensing to monitor cellular growth with unprecedented… More

Rapid Detection of Bacterial Contamination in Platelets

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ronald J. Rieder
Award Amount: $48,595.00
Abstract:
DESCRIPTION (provided by applicant): The development of a rapid and simple method for the diagnostic testing of pathogenic bacteria in platelet products is proposed. The technical approach is based on a novel implementation of impedance sensing to monitor cellular growth with unprecedented… More

Rapid Diagnostic Testing of Urinary Tract Infections

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ronald J. Rieder
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The development of a new rapid diagnostic method for testing the antibiotic susceptibility of urinary tract infections is proposed. The technical approach is based on a novel implementation of impedance sensing to monitor cellular growth with exceptional… More

SBIR Phase I: Early Growth Metabolic Responses of Mycobacteria

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: NSF
Principal Investigator: Ronald J. Rieder, Dr
Award Amount: $100,000.00
Abstract:
This Small Business Innovation Research Phase I project describes a method for the drug susceptibility testing of mycobacteria having speed and simplicity. The technical approach is based on a novel implementation of impedance sensing to monitor cellular growth with exceptional sensitivity and… More

SBIR Phase I: Rapid Antibiotic Suceptibility Testing of Sexually Transmitted Infections

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: NSF
Principal Investigator: Ronald J. Rieder, Dr
Award Amount: $100,000.00
Abstract:
This Small Business Innovation Research (SBIR) Phase I project proposes the development of a new test to diagnose pathogenic microorganisms causing sexually transmitted infections at the point-of-care in near-real time. The technical approach is based on a novel implementation of impedance sensing… More

Diagnosis of Extra-Pulmonary Tuberculosis in HIV Patients

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ronald J. Rieder
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The diagnosis of tuberculosis (TB) in individuals co-infected with human immunodeficiency virus is significantly challenged by the increased prevalence of extra-pulmonary forms of TB in severely immuno- suppressed pati ents. A cost-effective method for the rapid… More

SBIR Phase II: Early Growth Metabolic Responses of Mycobacteria

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: NSF
Principal Investigator: Ronald J. Rieder, PhD
Award Amount: $429,080.00
Abstract:
This SBIR Phase II research project develops a new rapid, nonmolecular method for quickly testing the drug susceptibility of Mycobacteria tuberculosis, the bacterium causing the epidemic disease tuberculosis (TB). Currently, all measurements for determining drug susceptibility - essential for… More

Rapid Diagnostic Testing of Urinary Tract Infections

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ronald J. Rieder
Award Amount: $750,000.00
Abstract:
DESCRIPTION (provided by applicant): Abstract The continued development of a rapid diagnostic method for testing the antibiotic susceptibility of urinary tract infections in near real-time is proposed. Currently, all methods for determining antibiotic susceptibility rely exclusively… More

Rapid Testing of Drug-Resistant BCR-ABL(+)Leukemia Cells

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ronald J. Rieder – 781-933-3635
Award Amount: $199,691.00
Abstract:
DESCRIPTION (provided by applicant): Resistance to chemotherapeutic drugs is an ongoing problem that results in eventual treatment failures or suboptimal patient outcomes. In cancer cells treated with drugs to which they are sensitive, the stress responseis the first step in the subsequent cascade… More

Rapid Testing of Drug Resistant BCR-ABL(+) Leukemia Cells

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ronald J. Rieder – 781-933-3635
Award Amount: $1,020,897.00
Abstract:
DESCRIPTION (provided by applicant): Resistance to chemotherapeutic drugs is an ongoing problem that results in eventual treatment failures or suboptimal patient outcomes. Approximately one-quarter of BCR-ABL(+) leukemia patients demonstrate evidence of resistance to imatinib mesylate either at… More